US FDA Approved Lung Cancer Therapy of Takeda
Takeda Pharmaceutical Company Limited announced, the US FDA has given the authorization to EXKIVITY (mobocertinib) for the purpose of treating the adult patients with the metastatic non-small cell lung cancer (NSCLC). The EXKIVITY has been approved under the Accelerated Approval that has been based on the overall response rate, and the continued approval for the […]
Continue Reading